top of page

Get Molecular Testing - Ontario

As of July 1st, 2024, Ontario patients living with cholangiocarcinoma will be able to access molecular testing from UHN’s Laboratory Medicine Program (UHN-LMP), in partnership with the C3. UHN-LMP uses a “Custom Solid Tumour (CST) v1 Panel”, which can detect FGFR2 fusions and additional DNA/RNA biomarkers (see below for full list).


Patients and treating physician will receive a complete clinical report indicating Tier I (variants of strong clinical significance) and Tier II (variants of potential clinical significance) alterations in DNA and RNA biomarkers.

To be eligible for C3 funded testing, the patient must be a member of the C3 and physicians must submit a C3 Patient Attestation form and UHN-LMP Test Requisition Form.

Important Information:

  • Patients must be a "C3 Member" and have signed the C3 non-research consent

    • Please ask your patients to contact us if they haven't already​

  • On Page 1 of the UHN-C3 Test Requisition Form​,    you will find information on Sample Requirements

  • On Page 2 of the UHN-C3 Test Requisition Form, please check only "Cholangiocarcinoma (Hepatobiliary)"​


Links for UHN-LMP x C3

Contact and Assistance Information:

​                *Note: testing through C3 will also return the                       list of genes at the bottom of this page, even                     though the TRF says "FGFR2 Only"

  • Completed Test Requisition Forms should be sent to:

    • Toronto General Hospital
      Eaton Wing 11-444, 200 Elizabeth Street
      Toronto, Ontario, M5G 2C4
      Attn: Dr. Shamini Selvarajah
      Phone: (416) 340-4800 x5739
      Fax: (416) 340-4473 Genome Diagnostics


*UHN-LMP provides Clinical-Grade Molecular Testing (CAP# 7175217/CLIA# 99D1106115)

bottom of page